Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary endpoints in adults with moderate-to-severe disease.
| Ticker |
Sentiment |
Impact |
|
REGN
|
Neutral
|
3 %
|
|
META
|
Neutral
|
1 %
|
|
SNY
|
Neutral
|
15 %
|
